ATAI News

The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL) priced at the midpoint to raise $425 million at a $4.7 billion market cap. The company is using proprietary genetic and...read more

ATAI Life Sciences, a biotech platform focused on psychedelics and other therapies for mental health, raised $225 million by offering 15 million shares at $15, the high end of the range of $13 to $15. The company offered 0.7 million more shares than anticipated. ATAI was founded as a response to unmet need and lack of innovation in the mental health treatment landscape, as well as...read more

Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise $425 million at a $4.7 billion market cap. The company is using proprietary genetic and epigenetic reprogramming to develop T...read more

ATAI Life Sciences, a biotech platform focused on psychedelics and underused therapies for psychiatric disorders, announced terms for its IPO on Friday. The Berlin, Germany-based company plans to raise $200 million by offering 14.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, ATAI Life Sciences would command a fully diluted market value...read more